Written informed consent provided;
Male or female patients aged 18-80 years;
Diagnosis with generalized myasthenia gravis;
MGFA Class II, III, or IVa;
AChR-Ab or MuSK-Ab positive;
A total MG-ADL score of ≥ 6 with less than 50% of the total score due to ocular symptoms;
QMG ≥ 8, with ≥ 4 items score at least 2;
Have been on a stable MG SoC regimen.
Exclusion Criteria:
Patients with autoimmune diseases other than MG;
Abnormal laboratory results;
Significant cardiovascular disease, liver, kidney, respiratory, endocrine or hematologic disease, or other medical conditions that, in the opinion of the investigator, would preclude the subject's participation in the study or require hospitalization during the study;
Acute or chronic infection requiring treatment;
Current active hepatitis;
HIV antibody positive;
Current thymoma-associated immunodeficiency syndrome (Good's syndrome) or thymic surgery within 6 months prior to screening;
Received or plan to receive any live vaccine within 3 months prior to randomization;
Patients with malignant tumors;
Allergy to biological products of human origin;
Participation in any clinical trial 28 days prior to randomization or within 5 times the half-life of an investigational drug (whichever is longer);
Pregnant or lactating women, and those intending to become pregnant during the trial;
Patients considered unsuitable by the investigator to participate in the trial (e.g., patients with severe mental disorders);
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Source : Importé depuis le centre
Cohortes
Thérapie ou Intervention proposée
Cohortes
Nom
Condition médicale
Traitement
État du recrutement
Telitacicept
Donnée non disponible
Participants will receive subcutaneous Telitacicept 240 mg once a week for a total of 48 doses in addition to MG SoC.
Inconnu
Placebo
Donnée non disponible
Participants will receive subcutaneous placebo once a week for a total of 24 doses (part A) and then weekly subcutaneous Telitacicept 240 mg for 24 doses (part B) in addition to MG SoC.
Inconnu
Telitacicept
État du recrutement
unknown
Participants will receive subcutaneous Telitacicept 240 mg once a week for a total of 48 doses in addition to MG SoC.
Placebo
État du recrutement
unknown
Participants will receive subcutaneous placebo once a week for a total of 24 doses (part A) and then weekly subcutaneous Telitacicept 240 mg for 24 doses (part B) in addition to MG SoC.
Données à jour depuis :
19 octobre 2023
Description de l'étude
Description de l'étude
Résumé de l'étude
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in the treatment of patients with generalized myasthenia gravis.
Source : Importé depuis le centre
This study consists of a screening period, a double-blind treatment period (part A) and an open-label treatment period (part B). After screening, eligible subjects will be randomized in a 1: 1 ratio to receive either subcutaneous Telitacicept 240 mg or placebo once a week for 24 doses (part A). Completing part A, subjects will automatically enter part B. In part B, all subjects will receive weekly subcutaneous Telitacicept 240 mg for 24 weeks.
Source : Importé depuis le centre
Centres participants
Sites
Centres participants
10
affichés
sur
51
centres
AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE
Nanchong
SICHUAN, CHINA
Recrutement local
État du recrutement:
OUVERT
Coordonnées pour le recrutement
Donnée non disponible
Contacts locaux
Donnée non disponible
AFFILIATED HOSPITAL OF ZUNYI MEDICAL UNIVERSITY
Zunyi
GUIZHOU, CHINA
Recrutement local
État du recrutement:
OUVERT
Coordonnées pour le recrutement
Donnée non disponible
Contacts locaux
Donnée non disponible
ANHUI PROVINCIAL HOSPITAL
Hefei
ANHUI, CHINA
Recrutement local
État du recrutement:
OUVERT
Coordonnées pour le recrutement
Donnée non disponible
Contacts locaux
Donnée non disponible
BEIJING HOSPITAL
Beijing
BEIJING, CHINA
Recrutement local
État du recrutement:
OUVERT
Coordonnées pour le recrutement
Donnée non disponible
Contacts locaux
Donnée non disponible
CHINA-JAPAN UNION HOSPITAL OF JILIN UNIVERSITY
Changchun
JILIN, CHINA
Recrutement local
État du recrutement:
OUVERT
Coordonnées pour le recrutement
Donnée non disponible
Contacts locaux
Donnée non disponible
DALIAN MUNICIPAL CENTRAL HOSPITAL
Dalian
LIAONING, CHINA
Recrutement local
État du recrutement:
OUVERT
Coordonnées pour le recrutement
Donnée non disponible
Contacts locaux
Donnée non disponible
FIRST AFFILIATED HOSPITAL OF XINJIANG MEDICAL UNIVERSITY
Urumqi
XINJIANG, CHINA
Recrutement local
État du recrutement:
OUVERT
Coordonnées pour le recrutement
Donnée non disponible
Contacts locaux
Donnée non disponible
FUJIAN MEDICAL UNIVERSITY UNION HOSPITAL
Fuzhou
FUJIAN, CHINA
Recrutement local
État du recrutement:
OUVERT
Coordonnées pour le recrutement
Donnée non disponible
Contacts locaux
Donnée non disponible
HENAN PROVINCIAL PEOPLE'S HOSPITAL
Zhengzhou
OTHER, CHINA
Recrutement local
État du recrutement:
OUVERT
Coordonnées pour le recrutement
Donnée non disponible
Contacts locaux
Donnée non disponible
HUASHAN HOSPITAL AFFILIATED TO FUDAN UNIVERSITY
Shanghai
SHANGHAI, CHINA
Recrutement local
État du recrutement:
OUVERT
Coordonnées pour le recrutement
Donnée non disponible
Contacts locaux
Donnée non disponible
Centres participants
Source d'information
Dernière modification :
19 octobre 2023
Données à jour depuis :
19 oct.
Origine des données :
clinicaltrials.gov